Scientia Advisors in the News

---

Publications

---

Press Releases

---

Events

---

Luminary Insights

---

Media Contact

---

Conferences

MassBio Personalized Medicine Summit: Harry Glorikian to Moderate Panel on Business and Market Challenges

Topic:

Business and Market Challenges

It is often argued that personalized medicine will shrink markets because a tailored approach will circumscribe the number of patients eligible for therapy, resulting in reduced profits. On the other hand, with better validated biomarkers, drug development costs will decrease because better patient selection will produce smaller trials at reduced cost. All of this is predicated on new targeted therapies.

This panel will examine the strategic, economic, and market challenges of a constantly shifting landscape and how this will impact:

• Innovation and lifecycle management of both generics and branded drugs
• Market size and revenue
• The costs of prospective trials to adequately validate biomarkers

Panelists:

Harry Glorikian, Founder and managing partner, Scientia Advisors - Moderator
Bruce Booth, Partner, Atlas Ventures
John McDonough, Chief Executive Officer, T2 Biosystems
Kristin Pothier, Vice President, Healthcare Advances
Dr. Robert Wassman, Chief Medical Officer, Helicos Biosciences

Learn More »